Evidence map›Paper›PMID 30713801›Full record

ArticleOncoimmunology

Pre-clinical development of

Hector Terán-Navarro, Ricardo Calderon-Gonzalez, David Salcines-Cuevas, Isabel García, Marco Marradi, Javier Freire, Erwan Salmon, Mar Portillo-Gonzalez, Elisabet Frande-Cabanes, Almudena García-Castaño and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncoimmunology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Modern Aspects of Immunotherapy with Checkpoint Inhibitors in Melanoma.International journal of molecular sciences · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 1 country.

Hector Terán-NavarroGroup of Listeria based Nanovaccines and cellular vaccines and their applications in biomedicine, Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Cantabria, Spain.
Ricardo Calderon-GonzalezGroup of Listeria based Nanovaccines and cellular vaccines and their applications in biomedicine, Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Cantabria, Spain.ORCID 0000-0003-0841-3814
David Salcines-CuevasGroup of Listeria based Nanovaccines and cellular vaccines and their applications in biomedicine, Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Cantabria, Spain.ORCID 0000-0003-2627-0597
Isabel GarcíaBionanoplasmonics Laboratory, CIC biomaGUNE and Biomedical Research Networking Center in Bioengineering, Nanomaterials and Nanomedicine (CIBER-BBN), Donostia-San Sebastián, Gipuzkoa, Spain.
Marco MarradiBionanoplasmonics Laboratory, CIC biomaGUNE and Biomedical Research Networking Center in Bioengineering, Nanomaterials and Nanomedicine (CIBER-BBN), Donostia-San Sebastián, Gipuzkoa, Spain.ORCID 0000-0003-0831-6942
Javier FreireServicio de Anatomía Patológica, Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain.
Erwan SalmonGroup of Listeria based Nanovaccines and cellular vaccines and their applications in biomedicine, Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Cantabria, Spain.
Mar Portillo-GonzalezGroup of Listeria based Nanovaccines and cellular vaccines and their applications in biomedicine, Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Cantabria, Spain.ORCID 0000-0002-6346-4836
Elisabet Frande-CabanesGroup of Listeria based Nanovaccines and cellular vaccines and their applications in biomedicine, Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Cantabria, Spain.ORCID 0000-0003-1748-0584
Almudena García-CastañoServicio de Oncología Médica, Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain.
Virginia Martinez-CallejoServicio de Farmacia Hospitalaria, Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain.
Javier Gomez-RomanServicio de Anatomía Patológica, Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain.
Raquel TobesOh no Sequences! Research Group, Era7 Bioinformatics, Granada, Andalucia, Spain.ORCID 0000-0001-7032-8720
Fernando RiveraServicio de Oncología Médica, Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain.
Sonsoles Yañez-DiazGroup of Listeria based Nanovaccines and cellular vaccines and their applications in biomedicine, Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Cantabria, Spain.
Carmen Álvarez-DomínguezGroup of Listeria based Nanovaccines and cellular vaccines and their applications in biomedicine, Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Cantabria, Spain.
Instituto de Investigación Marqués de Valdecilla · ESMarqués de Valdecilla University Hospital · ESCIC biomaGUNE · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gold glyconanoparticles loaded with the listeriolysin O peptide 91-99 (GNP-LLO

Indexed as

immunotherapyListeriamelanomananoparticlestherapeutic vaccination

Identifiers

PMID30713801
PMCPMC6343812
OpenAlexW2899553135

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.